Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 6Recruiting 4Not yet recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Rectal Neoplasms 3Lung Neoplasms 2Carcinoma, Hepatocellular 2Upper Tract Urothelial Carcinoma 1Unresectable Hepatocellular Carcinoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Sarcoma 1Radiation Injuries 1Pathologic Complete Response 1Pancreatic Cancer Liver Metastases 1Neoadjuvant Immunotherapy 1Muscle-invasive Bladder Cancer 1Locally Advanced Rectal Adenocarcinoma 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Carcinoma 1Hyperthermia 1HER2-Negative Locally Advanced Breast Cancer 1Gynecologic Cancers 1Gastrointestinal Neoplasms 1Gastric Cancer With Liver Metastases 1Esophageal Squamous Cell Carcinoma 1Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Rectal Cancer 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 10tislelizumab 9apatinib 9regorafenib 6camrelizumab 6donafenib 5atezolizumab 5Immune Checkpoint Inhibitors 4Hepatectomy 4cabozantinib 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2durvalumab 2anlotinib 2Surgical Procedures, Operative 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × Immunotherapy × Clear all
NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Tongji Hospital

Phase 1/2 Not yet recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07156617 2025-09-05

A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data

The First Affiliated Hospital of Zhengzhou University

Not yet recruiting
2,000 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡